Pancreatic Cancer Research

ResearcherTokai UniversityNo recent work listed

Naoya Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4332-5254; OpenAlex author ID A5074064898. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 10

  1. Sensitivity of endoscopic ultrasound-guided fine-needle aspiration cytology and biopsy for a diagnosis of pancreatic ductal adenocarcinoma: A comparative analy… Last author DOI 10.1111/pin.13328↗
  2. miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. Last author DOI 10.1038/s41598-022-22950-2↗
  3. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2020-207002↗
  4. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  5. Cancer-associated fibroblasts are a useful cytological finding for diagnosing pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cyt.12868↗
  6. Ganglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage. Co-author DOI 10.1038/s41598-019-55867-4↗
  7. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-017-1618-3↗
  8. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2016-204028↗
  9. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis. Co-author DOI 10.1007/s00595-015-1126-2↗
  10. Positive Intraoperative Peritoneal Lavage Cytology is a Negative Prognostic Factor in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study. Last author DOI 10.3389/fonc.2015.00182↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichi Hirabayashi · 8 shared papers, 2015–2022 · strength 0.76
  2. Toshio Nakagohri · 6 shared papers, 2015–2022 · strength 0.56
  3. Aya Kawanishi · 5 shared papers, 2017–2022 · strength 0.55
  4. Tsubasa Saika · 3 shared papers, 2020–2022 · strength 0.40
  5. Hideki Izumi · 3 shared papers, 2015–2023 · strength 0.31
  6. Masashi Morimachi · 2 shared papers, 2021–2022 · strength 0.29
  7. Tetsuya Mine · 3 shared papers, 2015–2018 · strength 0.20
  8. Misuzu Yamada · 3 shared papers, 2015–2018 · strength 0.20
  9. Masaki Miyazawa · 1 shared paper, 2022 · strength 0.16
  10. Tomoko Sugiyama · 1 shared paper, 2023 · strength 0.16
  11. Hiroyuki Ito · 1 shared paper, 2023 · strength 0.16
  12. Tatehiro Kagawa · 1 shared paper, 2021 · strength 0.13
  13. Yuji Heike · 1 shared paper, 2020 · strength 0.10
  14. Yoshinori Ino · 1 shared paper, 2020 · strength 0.10
  15. Yoji Kishi · 1 shared paper, 2020 · strength 0.10
  16. Shutaro Hori · 1 shared paper, 2020 · strength 0.10
  17. Kazuaki Shimada · 1 shared paper, 2020 · strength 0.10
  18. Satoshi Nara · 1 shared paper, 2020 · strength 0.10
  19. Toshihiko Torigoe · 1 shared paper, 2020 · strength 0.10
  20. Nobuyoshi Hiraoka · 1 shared paper, 2020 · strength 0.10
  21. Minoru Esaki · 1 shared paper, 2020 · strength 0.10
  22. Masashi Toyoda · 1 shared paper, 2019 · strength 0.09
  23. Fujiya Gomi · 1 shared paper, 2019 · strength 0.09
  24. Norihiko Sasaki · 1 shared paper, 2019 · strength 0.09
  25. Toshiyuki Ishiwata · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.